Global Blood Therapeutics Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
457
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$5.7B
Global Blood Therapeutics General Information
Description
Global Blood Therapeutics Inc operates in the healthcare sector of the United States. It discovers and develops novel therapeutics to address blood-based disorders. GBT440, its lead drug candidate targets the underlying mechanism of red blood cell (RBC) sickling, which provides the potential to treat sickle cell disease. GBT440. an oral, once-daily therapy arrests abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. In addition, the company is engaged in other research and development activities targeted at hereditary angioedema and owns exclusively licensed rights to its portfolio of product candidates in the United States, Europe, and other major markets.
Contact Information
Website
www.gbt.comCorporate Office
- 181 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 181 Oyster Point Boulevard
- South San Francisco, CA 94080
- United States
Global Blood Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 05-Oct-2022 | $5.7B | Completed | Generating Revenue | ||
| 10. Debt - General | 01-Dec-2019 | Completed | Generating Revenue | |||
| 9. 2PO | 11-Dec-2018 | Completed | Generating Revenue | |||
| 8. Secondary Transaction - Open Market | 31-Mar-2018 | Completed | Generating Revenue | |||
| 7. 2PO | 12-Mar-2018 | Completed | Generating Revenue | |||
| 6. Merger/Acquisition | 08-Mar-2017 | Cancelled | Pre-Clinical Trials | |||
| 5. 2PO | 19-Jan-2017 | Completed | Pre-Clinical Trials | |||
| 4. 2PO | 20-Jun-2016 | Completed | Pre-Clinical Trials | |||
| 3. IPO | 12-Aug-2015 | $120M | $218M | Completed | Pre-Clinical Trials | |
| 2. Early Stage VC (Series B) | 06-Jan-2015 | $48M | $97.9M | Completed | Startup |
Global Blood Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A |
Global Blood Therapeutics Comparisons
Industry
Financing
Details
Global Blood Therapeutics Competitors (10)
One of Global Blood Therapeutics’s 10 competitors is Merck & Co., a Corporation company based in Rahway, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| Geron | Formerly VC-backed | Foster City, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Bristol-Myers Squibb | Corporation | Princeton, NJ |
Global Blood Therapeutics Patents
Global Blood Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4727555-A1 | (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease | Pending | 13-Jun-2023 | ||
| US-20260306503-A1 | (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease | Pending | 13-Jun-2023 | ||
| WO-2024256964-A1 | (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease | Inactive | 13-Jun-2023 | ||
| AU-2022408097-A1 | Methods of administering a modulator of hemoglobin | Active | 10-Dec-2021 | ||
| AU-2022408097-B2 | Methods of administering a modulator of hemoglobin | Active | 10-Dec-2021 | A61K31/5377 |
Global Blood Therapeutics Signals
Global Blood Therapeutics Former Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aisling Capital | Venture Capital | Minority | ||
| Avoro Capital | Venture Capital | Minority | ||
| Cowen Healthcare Investments | Venture Capital | Minority | ||
| Deerfield Management | Venture Capital | Minority | ||
| Fidelity | Corporation | Minority |
Global Blood Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
15.64 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Global Blood Therapeutics FAQs
-
When was Global Blood Therapeutics founded?
Global Blood Therapeutics was founded in 2011.
-
Where is Global Blood Therapeutics headquartered?
Global Blood Therapeutics is headquartered in South San Francisco, CA.
-
What is the size of Global Blood Therapeutics?
Global Blood Therapeutics has 457 total employees.
-
What industry is Global Blood Therapeutics in?
Global Blood Therapeutics’s primary industry is Drug Discovery.
-
Is Global Blood Therapeutics a private or public company?
Global Blood Therapeutics is a Private company.
-
What is the current valuation of Global Blood Therapeutics?
The current valuation of Global Blood Therapeutics is .
-
What is Global Blood Therapeutics’s current revenue?
The current revenue for Global Blood Therapeutics is .
-
How much funding has Global Blood Therapeutics raised over time?
Global Blood Therapeutics has raised $1.05B.
-
Who are Global Blood Therapeutics’s investors?
Aisling Capital, Avoro Capital, Cowen Healthcare Investments, Deerfield Management, and Fidelity are 5 of 11 investors who have invested in Global Blood Therapeutics.
-
Who are Global Blood Therapeutics’s competitors?
Merck & Co., Agenus, Geron, Genentech, and Bristol-Myers Squibb are some of the 10 competitors of Global Blood Therapeutics.
-
When was Global Blood Therapeutics acquired?
Global Blood Therapeutics was acquired on 05-Oct-2022.
-
Who acquired Global Blood Therapeutics?
Global Blood Therapeutics was acquired by Pfizer.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process